{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:31:34Z","timestamp":1788489094632,"version":"build-2803163510"},"reference-count":53,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2018,5,4]]},"DOI":"10.1080\/13696998.2017.1421546","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T13:25:44Z","timestamp":1514294744000},"page":"450-467","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy"],"prefix":"10.1080","volume":"21","author":[{"given":"Sebastian","family":"Gonzalez-McQuire","sequence":"first","affiliation":[{"name":"Amgen (Europe) GmbH, Zug, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwee","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London, London, UK;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Leleu","sequence":"additional","affiliation":[{"name":"Public Health Expertise, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco S.","family":"Mennini","sequence":"additional","affiliation":[{"name":"Faculty of Economics, Economic Evaluation and HTA, Centre for Economic and International Studies, University of Rome Tor Vergata, Rome, Italy;"},{"name":"Institute for Leadership and Management in Health, Kingston University, Surrey, UK;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Flinois","sequence":"additional","affiliation":[{"name":"Kantar Health, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Gazzola","sequence":"additional","affiliation":[{"name":"Kantar Health, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Schoen","sequence":"additional","affiliation":[{"name":"Amgen (Europe) GmbH, Zug, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Campioni","sequence":"additional","affiliation":[{"name":"Amgen (Europe) GmbH, Zug, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"DeCosta","sequence":"additional","affiliation":[{"name":"Amgen Ltd, Uxbridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Fink","sequence":"additional","affiliation":[{"name":"Kantar Health, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,1,10]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcm077"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt297"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.07.005"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0042"},{"key":"CIT0006","first-page":"204","volume":"8","author":"Roy A","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.89"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1031732"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2015.1122259"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12571"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S43373"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12020"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136207"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1177\/030089161309900434"},{"key":"CIT0015","unstructured":"NHS Health Research Authority. What approvals and decisions do I need? London, United Kingdom. Available at: https:\/\/www.hra.nhs.uk\/approvals-amendments\/what-approvals-do-i-need\/"},{"key":"CIT0016","volume-title":"The EFGCP report on the procedure for the ethical review of protocols for clinical research projects in Europe","author":"European Forum for Good Clinical Practice.","year":"2011"},{"key":"CIT0017","volume-title":"Good Epidemiological Practice (GEP)","author":"International Epidemiological Association."},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14193"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213"},{"key":"CIT0020","volume-title":"NICE technology appraisal guidance TA129. Bortezomib monotherapy for relapsed multiple myeloma","author":"National Institute for Health and Care Excellence.","year":"2007"},{"key":"CIT0021","volume-title":"NICE technology appraisal guidance TA171. Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy NICE","author":"National Institute for Health and Care Excellence.","year":"2009"},{"key":"CIT0022","volume-title":"NICE technology appraisal guidance TA338. Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib","author":"National Institute for Health and Care Excellence.","year":"2015"},{"key":"CIT0023","volume-title":"NHS reference costs 2013 to 2014","author":"Department of Health."},{"key":"CIT0024","volume-title":"Laboratory handbook and price list; a brief guide for clinical and laboratory staff","author":"Service C.","year":"2010"},{"key":"CIT0025","volume-title":"MedicinesComplete (online)","author":"Press P."},{"key":"CIT0026","volume-title":"Classification Commune des Actes M\u00e9dicaux","author":"L\u2019Assurance Maladie"},{"key":"CIT0027","volume-title":"Base des M\u00e9dicaments et Infomations Tarifaires","author":"L\u2019Assurance Maladie"},{"key":"CIT0028","volume-title":"Nomenclature generale des actes professionnels (NGAP) restant en vigueur depuis la decision uncam du 11 mars 2005 presentation","author":"L\u2019Assurance Maladie","year":"2017"},{"key":"CIT0029","volume-title":"Biologie medicale nomencature des actes","author":"L\u2019Assurance Maladie","year":"2017"},{"key":"CIT0030","volume-title":"Echelle Nationale des Co\u00fbts","author":"France Ministry of Health."},{"key":"CIT0031","unstructured":"Codifa. Informatore Farmaceutico: Codifa - Informatore Farmaceutico. Milan, Italy. Available at: http:\/\/www.codifa.it\/"},{"key":"CIT0032","volume-title":"Elenco Medicinali di fascia A e H","author":"Agenzia Italiana del Farmaco (AIFA)."},{"key":"CIT0033","volume-title":"Allegato A alla Dgr n. 95 del 31 gennaio","author":"FILE F \u2013 Regione del Veneto.","year":"2012"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1007\/BF03320727"},{"key":"CIT0035","volume-title":"Allegato B al Decreto n. 47 del 22.5.2013","author":"Regione del Veneto."},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1186\/1824-7288-40-40"},{"key":"CIT0037","first-page":"109","volume":"4","author":"Garattini L","year":"2003","journal-title":"Farmecon Health Econ Ther Path"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7547-8-8"},{"key":"CIT0039","first-page":"572","volume":"16","author":"Vitale C","year":"2003","journal-title":"J Nephrol"},{"key":"CIT0040","volume-title":"R\u00e9f\u00e9rentiel Traitement My\u00e9lome Multiple","author":"Oncomip.","year":"2011"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"CIT0042","volume-title":"Levact","author":"European Medicines Agency.","year":"2011"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.002"},{"key":"CIT0044","volume-title":"National Cancer Drugs Fund List","author":"National Health Service Commissioning Board.","year":"2013"},{"key":"CIT0045","volume-title":"Revlimid (lenalidomide) summary of product characteristics","author":"Celgene.","year":"2012"},{"key":"CIT0046","volume-title":"Velcade\u00ae (bortezomib) summary of product characteristics","author":"Janssen-Cilag.","year":"2014"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1548-y"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23634"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.09.1119"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.09.1134"},{"key":"CIT0051","volume-title":"Kyprolis (carfilzomib) summary of product characteristics","author":"Amgen Europe B.V","year":"2017"},{"key":"CIT0052","volume-title":"Empliciti (elotuzumab): summary of product charateristics","author":"Bristol-Myers Squibb","year":"2016"},{"key":"CIT0053","volume-title":"DARZALEX (daratumumab): summary of product characteristics","author":"Janssen-Cilag","year":"2016"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2017.1421546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T00:27:39Z","timestamp":1599265659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2017.1421546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,10]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5,4]]}},"alternative-id":["10.1080\/13696998.2017.1421546"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2017.1421546","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}